 | | Vol. 14.40 – 17 October, 2023 |
| |
|
|
| To identify druggable regulators of immunosuppressive tumor immune microenvironment, researchers performed a kinome- and membranome-focused CRISPR screening using orthotopic PDAC models.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors demonstrated that CD47 receptor signaling inhibited insulin release from human as well as mouse pancreatic β cells, and that it could be pharmacologically exploited to boost insulin secretion in both models.
[Science Translational Medicine] |
|
|
|
| Antibody treatment in male rats and mice transgenic for human islet amyloid polypeptide (IAPP), and human islet-engrafted mouse models of type 2 diabetes triggered clearance of IAPP oligomers resulting in beta cell protection and improved glucose control.
[Nature Communications] |
|
|
|
| Researchers obtained reference data on amylase activity in pancreatic tissue and duodenal digesta in laboratory mice, rats and hamsters. In addition, digesta was stained with Lugol’s iodine to visualize starch in the process of degradation throughout the gastrointestinal tract.
[Scientific Reports] |
|
|
|
| Investigators interrogated the role of the Staphylococcal Nuclease and Tudor domain-containing protein (SND1) coregulator on controlling gene expression and β cell function in vitro.
[Islets] |
| |
|
|
| The authors demonstrated that treating PDAC cells with a Gln antagonist, 6-diazo-5-oxo-L-norleucine, led to a metabolic crisis in vitro.
[Nature Cancer] |
|
|
|
| Investigators identified 17,996 N6-methyladenosine (m6A) peaks with 195 hyper-methylated and 93 hypo-methylated in PDAC compared with adjacent normal tissues.
[Nature Communications] |
|
|
|
| Using patient-derived xenografts of KRAS- and MYC-driven pancreatic carcinoma, scientists showed that coinhibition of topoisomerase 1 and bromodomain-containing protein 4 (BRD4) synergistically induced tumor regression by targeting promoter pause release.
[Science Advances] |
|
|
|
| Researchers conducted a systematic and comprehensive analysis of all 24 human matrix metalloproteinases to identify suitable subtypes of MMPs as potential prognosis biomarkers and novel therapeutic targets in PDAC.
[Scientific Reports] |
|
|
|
|
| Scientists cover emerging treatment strategies in the management of metastatic PDAC. One of the main topics is the rigid and immunological cold tumor microenvironment of PDAC and the search for agents that impact this TME and/or engage the immune system.
[Expert Review of Anticancer Therapy] |
|
|
|
|
| University of California (UC) San Diego cancer biologist Tatiana Hurtado de Mendoza has been named the recipient of the 2023 Claugus Award for Medical Research.
[UC San Diego] |
|
|
|
|
| November 7 – 8, 2023
London, England, United Kingdom |
|
|
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | Texas Tech University Health Sciences Center El Paso – El Paso, Texas, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | The University of Tennessee – Memphis, Tennessee, United States |
|
|
|
| | Beth Israel Deaconess Medical Center & Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
